Sign In
Buy PCVX
$51.96
-0.150 (-0.288%)
At Close: Jun 23, 2026
Vaxcyte: Financial Durability And The Case For Disruption
09:26am, Tuesday, 16'th Dec 2025
Vaxcyte is positioned to disrupt the pneumococcal vaccine market with its engineered VAX-31, overcoming carrier suppression limitations faced by incumbents. PCVX's $2.7B cash position supports an aggr
Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head
Edgestream Partners L.P. Takes $1.61 Million Position in Vaxcyte, Inc. $PCVX
04:10am, Saturday, 06'th Dec 2025
Edgestream Partners L.P. purchased a new position in shares of Vaxcyte, Inc. (NASDAQ: PCVX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor
8,754 Shares in Vaxcyte, Inc. $PCVX Purchased by AXQ Capital LP
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP acquired a new position in shares of Vaxcyte, Inc. (NASDAQ: PCVX) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,754 shares of t
Bank of Montreal Can Buys 1,274 Shares of Vaxcyte, Inc. $PCVX
04:43am, Sunday, 16'th Nov 2025
Bank of Montreal Can boosted its stake in Vaxcyte, Inc. (NASDAQ: PCVX) by 4.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fir
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoin
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte's Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates
Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript
10:01pm, Sunday, 07'th Sep 2025
Vaxcyte, Inc. (NASDAQ:PCVX ) Cantor Global Healthcare Conference 2025 September 3, 2025 2:45 PM EDT Company Participants Grant Pickering - Co-Founder, CEO & Director Andrew Guggenhime - President & CF
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
07:30am, Wednesday, 03'rd Sep 2025
VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococ
Vaxcyte (PCVX) Q2 Loss Widens 11%
08:19pm, Wednesday, 06'th Aug 2025
Vaxcyte (PCVX) Q2 Loss Widens 11%
Following Interactions with FDA on VAX-31 Adult Program, Including End-of-Phase 2 Meeting, Company Finalizing Phase 3 Clinical Program to Validate VAX-31 as Potential New Standard-of-Care Adult PCV ;
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Wednesday, 07'th May 2025
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
08:00am, Thursday, 01'st May 2025
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacteri
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
02:10pm, Thursday, 10'th Apr 2025
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
08:25am, Tuesday, 01'st Apr 2025
The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.
